Transgenic production of heparin

Abstract

The disclosure provides methods, cells and transgenic non human mammals for the production of heparin. Specifically, the method comprising providing a transgenic non human mammal or mammary epithelial cells modified to express one or more heparin biosynthesis enzymes, and harvesting heparin produced. Further provided are the cells and transgenic non human mammals thereof as well as the heparin obtained from these cells or transgenic non human mammals.

Description

[0001] related application [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Serial No. 61 / 920,505, filed December 24, 2013, entitled "Transgenic Production of Heparin," the entire contents of which are incorporated herein by reference . field of invention [0003] The present application relates to the field of transgenic production of biological compounds. Background of the invention [0004] Heparin is a complex glycosaminoglycan widely used as an anticoagulant. Heparin is usually collected from the small intestine of animals or the lungs of bovines. However, there is a problem of heparin contamination. Thus, new methods for the production of heparin are needed. Summary of the invention [0005] In one aspect, the application provides methods, cells and transgenic mammals for the production of heparin. In one embodiment, a transgenic non-human mammal that produces heparin in its milk is provided. In one embodi...

AI Technical Summary

Problems solved by technology

However, there is the issue of heparin contamination

Images